Fumimasa Fukuta

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction

Koji Ichihara, Naoya Masumori, Fumimasa Fukuta et al. · The Journal of Urology · 2014 · 104 citations

Medicine, Pharmacotherapy, Urology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

Natural history of lower urinary tract symptoms in Japanese men from a 15‐year longitudinal community‐based study

Fumimasa Fukuta, Naoya Masumori, Mitsuru Mori et al. · British Journal of Urology · 2012 · 45 citations

Medicine, Endocrinology, Urology +11

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

Takashi Kobayashi, Katsuhiro Ito, Takahiro Kojima et al. · Cancer Immunology Immunotherapy · 2021 · 38 citations · Full text

Medicine, Oncology, Pharmacology +8